Edgar Lomax Co. VA Has $20.41 Million Stock Holdings in Pfizer Inc. $PFE

Edgar Lomax Co. VA decreased its stake in Pfizer Inc. (NYSE:PFE) by 43.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 805,400 shares of the biopharmaceutical company’s stock after selling 628,910 shares during the period. Edgar Lomax Co. VA’s holdings in Pfizer were worth $20,409,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at about $27,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter worth approximately $28,000. Finally, North Capital Inc. bought a new position in Pfizer in the first quarter worth approximately $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $25.16 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $143.05 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52. The stock has a 50 day moving average of $24.60 and a 200 day moving average of $24.42. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Wolfe Research increased their price target on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a report on Wednesday, April 30th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. TD Cowen cut their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a report on Tuesday, April 22nd. Finally, The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.